Phase I and pharmacokinetic study of cetuximab and irinotecan in children with refractory solid tumors: A study of the pediatric oncology experimental therapeutic investigators' consortium

Journal of Clinical Oncology

Volumn 27, Issue 30, 2009, Pages 5102-5108

  Trippett, Tanya M ^a   Herzog, Cynthia ^a   Whitlock, James A ^a   Wolff, Johannes ^a   Kuttesch, John ^a   Bagatell, Rochelle ^a   Hunger, Stephen P ^a   Boklan, Jessica ^a   Smith, Amy A ^a   Arceci, Robert J ^a   Katzenstein, Howard M ^a   Harbison, Christopher ^a   Zhou, Xiaofei ^a   Lu, Haolan ^a   Langer, Christiane ^a   Weber, Martin ^a   Gore, Lia ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CEFIXIME; CETUXIMAB; IRINOTECAN;

ABDOMINAL PAIN; ACNE; ADOLESCENT; ADULT; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CENTRAL NERVOUS SYSTEM TUMOR; CHEMOTHERAPY INDUCED EMESIS; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DEHYDRATION; DIARRHEA; DISEASE COURSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; FATIGUE; FEMALE; GROUPS BY AGE; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; INFANT; INFUSION SITE REACTION; LEUKOPENIA; MALE; MAXIMUM TOLERATED DOSE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NONHODGKIN LYMPHOMA; PEDIATRICS; PHARMACOLOGICAL PARAMETERS; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; SCHOOL CHILD; SEPSIS; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADOLESCENT; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; INFANT; MALE; MAXIMUM TOLERATED DOSE; NEOPLASMS;

EID: 77649175483     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.20.8975     Document Type: Article

References (45)

1. United States Cancer Statistics Working Group: United States Cancer Statistics: 1999-2004 Incidence and Mortality Web-based Report. Atlanta, GA, United States Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute, 2007. http://www.cdc.gov/ uscs
2. McGregor LM, Metzger ML, Sanders R, et al: Pediatric cancers in the new millennium: Dramatic progress, new challenges. Oncology 21:809-820, 2007
3. National Cancer Institute: Surveillance Epidemiology and End Results (SEER). http://seer.cancer.gov/
4. Ghanem MA, Van Der Kwast TH, Den Hollander JC, et al: Expression and prognostic value of epidermal growth factor receptor, transforming growth factor-alpha, and c-erb B-2 in nephroblastoma. Cancer 92:3120-3129, 2001
5. Yokoi A, McCrudden KW, Huang J, et al: Human epidermal growth factor receptor signaling contributes to tumor growth via angiogenesis in her2/neu-expressing experimental Wilms' tumor. J Pediatr Surg 38:1569-1573, 2003
6. Hughes DP, Thomas DG, Giordano TJ, et al: Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer Res 64:2047-2053, 2004
7. Ganti R, Skapek SX, Zhang J, et al: Expression and genomic status of EGFR and ErbB-2 in alveolar and embryonal rhabdomyosarcoma. Mod Pathol 19:1213-1220, 2006
8. Ganigi PM, Santosh V, Anandh B, et al: Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients. Pediatr Neurosurg 41:292-299, 2005
9. Tabori U, Rienstein S, Dromi Y, et al: Epidermal growth factor receptor gene amplification and expression in disseminated pediatric low-grade gliomas. J Neurosurg 103:357-361, 2005 (suppl)
10. Bredel M, Pollack IF, Hamilton RL, et al: Epidermal growth factor receptor expression and gene amplification in high-grade non-brainstem gliomas of childhood. Clin Cancer Res 5:1786-1792, 1999
11. Gilbertson RJ, Hill DA, Hernan R, et al: ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma. Clin Cancer Res 9:3620-3624, 2003
12. Mimeault M, Hauke R, Mehta PP, et al: Recent advances in cancer stem/progenitor cell research: Therapeutic implications for overcoming resistance to the most aggressive cancers. J Cell Mol Med 11:981-1011, 2007
13. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 21:2787-2799, 2003
14. Kurai J, Chikumi H, Hashimoto K, et al: Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res 13:1552-1561, 2007
15. Cunningham D, Humbled Y, Siena S, et al: Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345, 2004
16. Jonker DJ, O'Callaghan CJ, Karapetis CS, et al: Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048, 2007
17. Van Cutsem E, Nowacki M, Lang I, et al: Randomized phase III study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer (mCRC): The CRYSTAL trial. J Clin Oncol 25:164s, 2007 (suppl; abstr 4000)
18. Bonner JA, Harari PM, Giralt J, et al: Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354:567-578, 2006
19. Vermorken JB, Mesia R, Rivera F, et al: Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359:1116-1127, 2008
20. Vermorken JB, Trigo J, Hitt R, et al: Open-Label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 25:2171-2177, 2007
21. Pirker R, Szczesna A, von Pawel J, et al: FLEX: A randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26:6s, 2008 (suppl; abstr 3)
22. Blick SK, Scott LJ: Cetuximab: A review of its use in squamous cell carcinoma of the head and neck and metastatic colorectal canacer. Drugs 67:2585-2607, 2007
23. Vassal G, Couanet D, Stockdale E, et al: Phase II trial of irinotecan in children with relapsed or refractory rhabdomyosarcoma: A joint study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group. J Clin Oncol 25:356-361, 2007
24. Shitara T, Shimada A, Hanada R, et al: Irinotecan for children with relapsed solid tumors. Pediatr Hematol Oncol 23:103-110, 2006
25. Cosetti M, Wexler LH, Calleja E, et al: Irinotecan for pediatric solid tumors: The Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 24:101-105, 2002
26. Friedman HS, Keir ST, Houghton PJ: The emerging role of irinotecan (CPT-11) in the treatment of malignant glioma in brain tumors. Cancer 97:2359-2362, 2003 (suppl)
27. Furman WL, Stewart CF, Poquette CA, et al: Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 17:1815-1824, 1999
28. Prewett MC, Hooper AT, Bassi R, et al: Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 8:994-1003, 2002
29. National Cancer Institute: Common Terminology Criteria for Adverse Events v 3.0 (CTCAE). August 9, 2006. http://ctep.cancer.gov/forms/CTCAEv3.pdf
30. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
31. Gnekow AK: Recommendations of the Brain Tumor Subcommittee for the reporting of trials. Med Pediatr Oncol 24:104-108, 1995
32. Macdonald DR, Cascino TL, Schold SC Jr, et al: Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280, 1990
33. Fracasso PM, Burris H 3rd, Arquette MA, et al: A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: Pharmacokinetic and pharmacodynamic rationale for dosing. Clin Cancer Res 13:986-993, 2007
34. Ettlinger DE, Mitterhauser M, Wadsak W, et al: In vivo disposition of irinotecan (CPT-11) and its metabolites in combination with the monoclonal antibody cetuximab. Anticancer Res 26:1337-1341, 2006
35. Delbaldo C, Pierga JY, Dieras V, et al: Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma. Eur J Cancer 41:1739-1745, 2005
36. Tan AR, Moore DF, Hidalgo M, et al: Pharmacokinetics of cetuximab after administration of escalating single dosing and weekly fixed dosing in patients with solid tumors. Clin Cancer Res 12:6517-6522, 2006
37. Lobo ED, Hansen RJ, Balthasar JP: Antibody pharmacokinetics and pharmacodynamics. J Pharm Sci 93:2645-2668, 2004
38. Baselga J, Pfister D, Cooper MR, et al: Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 18:904-914, 2000
39. Chung KY, Chung KY, Shia J, Kemeny NE, et al: Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23:1803-1810, 2005
40. Lenz H-J, Van Cutsem E, Khambata-Ford S, et al: Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 24:4914-4921, 2006
41. Daw NC, Furman WL, Stewart CF, et al: Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 23:6172-6180, 2005
42. Freeman BB 3rd, Daw NC, Geyer JR, et al: Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer Invest 24:310-317, 2006
43. Van Cutsem E, Kohne C-H, Hitre E, et al: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408-1417, 2009
44. Bokemeyer C, Bondarenko I, Makhson A, et al: Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27:663-671, 2008
45. Karapetis CS, Khambata-Ford S, Jonker DJ, et al: K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359:1757-1765, 2008